Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2019.0018
• Publication Date: 2019-04-08T18:33:40Z
• Authors: Daniel G. Coit; John A. Thompson; Mark R. Albertini; Christopher Barker; William E. Carson; Carlo Contreras; Gregory A. Daniels; Dominick DiMaio; Ryan C. Fields; Martin D. Fleming; Morganna Freeman; Anjela Galan; Brian Gastman; Valerie Guild; Douglas Johnson; Richard W. Joseph; Julie R. Lange; Sameer Nath; Anthony J. Olszanski; Patrick Ott; Aparna Priyanath ...; Merrick I. Ross; April K. Salama; Joseph Skitzki; Jeffrey Sosman; Susan M. Swetter; Kenneth K. Tanabe; Evan Wuthrick; Nicole R. McMillian; Anita M. Engh
• Keywords: 03 medical and health sciences; Skin Neoplasms; Melanoma, Cutaneous Malignant; 0302 clinical medicine; Humans; Medical Oncology; Melanoma; 3. Good health

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.